You are here

Kymab

Sanofi reports setbacks to Denali, Kymab and Principia assets, delivering mix of misses and halts

Fierce Biotech

Fri, 10/27/23 - 11:36 am

Principia Biopharma

Sanofi's $1.1B eczema drug hits midphase goal, spurring talk of phase 3 and new indications

Fierce Biotech

Tue, 06/27/23 - 10:09 am

clinical trials

As Sanofi prunes pipeline, ex-Alexion crew at Rallybio picks up anemia drug

Endpoints

Tue, 05/10/22 - 10:56 am

Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema

Pharmaforum

Fri, 10/1/21 - 10:48 am

clinical trials

Quiet times return for biopharma takeouts

EP Vantage

Wed, 04/14/21 - 09:26 am

Five Prime Therapeutics

Gilead Sciences

Horizon Therapeutics

Jazz Pharmaceutical

Sanofi inks $1.1B Kymab buyout to bag midphase eczema drug

Fierce Biotech

Mon, 01/11/21 - 09:57 am

atopic dermatitis

monoclonal antibodies